Why is Merck focusing on new assets beyond Keytruda?

Because Keytruda's patent is expiring soon, potentially causing a significant revenue drop, so Merck is developing alternative therapies.

What percentage of Merck's revenue does Keytruda account for?

Keytruda accounts for over 40% of Merck's revenue.

Merck Showcases Solid Tumour Data at ASCO26, Highlighting Pipeline

At ASCO26, Merck (MRK) unveiled positive solid tumour data for Keytruda and other pipeline assets, signaling a strategy to address Keytruda's upcoming exclusivity loss.

June 5, 2026

2 min read

Source: Pharmaceutical Technology

At the American Society of Clinical Oncology (ASCO26) conference, Merck & Co. (MRK) presented new clinical data for its flagship drug Keytruda (pembrolizumab) in solid tumours, alongside early-stage assets designed to diversify its oncology portfolio.

Keytruda Data

Recent trials showed Keytruda's efficacy in multiple solid tumour types, including non-small cell lung cancer and bladder cancer, reinforcing its role as a first-line therapy in these indications.

Pipeline Assets

Merck also highlighted experimental compounds such as an LAG-3 inhibitor and an anti-TIGIT agent, aimed at providing new treatment options after Keytruda's patent expiry expected later this decade.

Competitive Landscape

Merck faces competition from Bristol Myers Squibb (BMY) and Merck KGaA in solid tumours, but its deep pipeline may offer a competitive edge.

Potential Impact

Success of these new assets could mitigate the impact of Keytruda's patent loss, which accounts for over 40% of Merck's revenue. Investors are closely watching trial developments.

Frequently Asked Questions

Merck presented positive data for Keytruda in solid tumours like lung and bladder cancer, along with new assets such as an LAG-3 inhibitor.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.